American Democratic presidential candidate Andrew Yang has publicly expressed his support for drug policy reform around psilocybin mushrooms! After meeting with a U.S. military veteran in Davenport Iowa in December 2019, Yang tweeted “We should explore making psilocybin mushrooms legal for medical and therapeutic use particularly for veterans.” Yang has also tweeted referencing praise for psilocybin from the FDA (who designated it as a “breakthrough therapy” for Major Depressive Disorder (MDD)). This stance is fairly consistent with the rest of his platform, which includes federally legalizing marijuana, medicare for all, and the famous freedom dividend.
This bold drug policy stance aligns with the interests of advocates in over 130 American cities who have or are in the process of locally decriminalizing psilocybin. In May 2019, Denver voters approved a ballot measure making their city the first in the country to decriminalize. The Oakland City Council soon followed by passing a resolution decriminalizing not only psychedelic mushrooms but also other entheogenic substances such as ibogaine, ayahuasca and mescaline. The precedent set by these two major cities quickly spurred initiatives activists across the country to pursue similar far-reaching psychedelic reform measures. Oregon activists are currently collecting signatures to place a measure on the state’s 2020 ballot that would legalize psilocybin for therapeutic use, meanwhile advocates in California are working to to more broadly legalize the psychoactive fungus on a statewide level.
The primary factor in psilocybins accelerated acceptance by authorities is its safety and efficacy as a treatment for a host of psychological conditions, including depression, anxiety, OCD, addiction, and eating disorders. A quickly growing body of evidence suggests that as little as 1 (high) dose of psilocybin can produce a transformative experience that gives lasting positive effects on mood, social connectivity, mental well-being, and even the alteration of moral values. These studies have been conducted at surprisingly prestigious institutions, like Harvard, Stanford, Yale, Johns Hopkins, Perdue, University of Toronto, The Heffter Institute, and The Usona Institute.
*Some of the universities studies psilocybin